The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer. The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small ...

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Historically, non-small cell lung cancer (NSCLC) treatment involved three modalities: surgery, radiation therapy and chemotherapy. In the last two decades, the treatment landscape of NSCLC has greatly ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...